OSAKA, Japan — (BUSINESS WIRE) — Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (「Takeda」) today announced findings from two new interim analyses of data from the Phase 3 HELP (…
New Data from the Phase 3 HELP Study Open-Label Extension Evaluate the Long-Term Safety and Efficacy of TAKHZYRO® (lanadelumab) in Reducing Hereditary Angioedema Attacks
OSAKA, Japan — (BUSINESS WIRE) — Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (「Takeda」) today announced findings from two new interim analyses of data from the Phase 3 HELP (…